Contact Us
Drug Search Results
More Filters [+]

Pidilizumab

Alternative Names: pidilizumab, ct-011, mdv-9300, mdv 9300, mdv9300
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PD-1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CureTech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pidilizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Pancreatic Cancer|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Renal Cell Carcinoma|Lymphoma, Non-Hodgkin|Hepatocellular Carcinoma|Multiple Myeloma|Hepatitis A|Glioma|Melanoma|Hepatitis C, Chronic

Phase 1: Breast Cancer|Ovarian Cancer|Sarcoma|Colorectal Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT01067287

P2

Active, not recruiting

Multiple Myeloma

2024-09-01

antiPD1brainad2- HMO-CTIL

P2

Unknown status

Glioma

2018-11-01

MDV9300-01

P2

Withdrawn

Diffuse Large B-Cell Lymphoma

2018-06-01

11-C-0100

P2

Terminated

Pancreatic Cancer

2017-01-01

Recent News Events

Date

Type

Title

07/12/2021

News Article

 Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

01/22/2019

News Article

 Piedmont Commences 25,000 Meter Drill Program Designed to Significantly Extend Project Life

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions